A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients with Primary IgA Nephropathy in Combination With Stable Background Therapy

  • Ryan, Jessica (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date29/11/22 → 28/11/27